Topics

MorphoSys AG: MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma

16:44 EDT 29 Apr 2019 | FinanzNachrichten

PLANEGG/MUNICH, GERMANY and SHANGHAI, CHINA / ACCESSWIRE / April 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based cl...

Original Article: MorphoSys AG: MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma

NEXT ARTICLE

More From BioPortfolio on "MorphoSys AG: MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma"

Quick Search